Russian Heart Failure Journal 2004year Levosimendan, a new drug for treatment of decompensated severe chronic heart failure
Levosimendan, a new drug for treatment of decompensated severe chronic heart failure
Belenkov Yu.N., Mareev V.Yu., Skvortsov A.A.
A very high level of morbidity and mortality is observed in admitted patients with decompensated chronic heart failure (CHF). Current strategy of managing CHF patients with acute decompensation should involve not only seeking for stabilization of their condition but also improving prognosis in this category of patients. Diuretics, peripheral vasodilators, catecholamines, milrinone as well as the vasopressin antagonists niseretide and levosimendan, which are currently at the stage of clinical trials, are used today for therapy of acute cardiac decompensation. By comparing pharmacodynamic and pharmacokinetic aspects of activity, advantages of the new inotropic agent levosimendan are considered as against conventional inotropic drugs. In addition, peculiarities of the drug use in the treatment of decompensated heart performance are presented, and the effect of the drug on morbidity and mortality (by data of studies LIDO, CASINO, and RUSSLAN) is analysed.